Related references
Note: Only part of the references are listed.Pretargeted Radioimmunotherapy Using Anti-CD45 Monoclonal Antibodies to Deliver Radiation to Murine Hematolymphoid Tissues and Human Myeloid Leukemia
John M. Pagel et al.
CANCER RESEARCH (2009)
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab
Ajay K. Gopal et al.
BLOOD (2008)
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy
John M. Pagel et al.
BLOOD (2008)
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas
Anastasia Pantelias et al.
BLOOD (2007)
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
John M. Pagel et al.
BLOOD (2006)
A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted Radioimmunotherapy of hematologic malignancies
YK Lin et al.
CANCER RESEARCH (2006)
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
JM Pagel et al.
BLOOD (2006)
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
A Nademanee et al.
BLOOD (2005)
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
A Forero et al.
BLOOD (2004)
Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma
JN Winter
CLINICAL LYMPHOMA (2004)
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas
JM Pagel et al.
BLOOD (2003)
Pretarget radiotherapy with an anti-CD25 antibody streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
ML Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Pretargeting radioinimunotherapy of a murine model of adult T-cell leukemia with the α-emitting radionuclide, bismuth 213
ML Zhang et al.
BLOOD (2002)
A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts
OW Press et al.
BLOOD (2001)
Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy
S Goshorn et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2001)
Internal dosimetry for systemic radiation therapy
DR Fisher
SEMINARS IN RADIATION ONCOLOGY (2000)
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity
DB Axworthy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL):: Initial phase I/II study results
PL Weiden et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2000)
Share Paper
